Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases

Jagadeshwar G. Reddy, Edward V. Loftus

Research output: Contribution to journalReview articlepeer-review

72 Scopus citations

Abstract

In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.

Original languageEnglish (US)
Pages (from-to)837-855
Number of pages19
JournalGastroenterology Clinics of North America
Volume35
Issue number4
DOIs
StatePublished - Dec 1 2006

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases'. Together they form a unique fingerprint.

Cite this